EyePoint: Uncompelling Non-Inferiority Strategy Vs. A Moving Aflibercept Target

EyePoint faces clinical, commercial hurdles despite DME, AMD progress and solid funding through 2027. Read why EYPT stock is ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer ...

Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early ...

Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting ...

Planet Labs PBC (PL) Analyst/Investor Day Transcript

Analyst/Investor Day October 16, 2025 9:00 AM EDTCompany ParticipantsCleo Palmer-PoronerWilliam Marshall - Co-Founder, CEO ...
BuzzFeed on MSN

If Your Beauty Routine Needs A Glow Up, Try These 35 Reviewer-Beloved Products

"Yummmmm" —your skin soaking up the bursting Vitamin C capsules in this TikTok-beloved moisturizer. View Entire Post › ...
BMJ

Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist

With a growing number ... types (non-small cell lung cancer, small cell lung cancer, renal cell carcinoma, urothelial carcinoma and triple-negative breast cancer). Individual patient-level data from ...